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DOI 10.1016/j.str.2007.10.008The automation of all steps in protein
crystallography—expression, purifica-
tion, crystallization, X-ray data collec-
tion, and analysis—has provided the
community with many new opportuni-
ties. The most obvious, now known as
structural genomics or structural pro-
teomics, is to define the three-dimen-
sional structures of representative pro-
teins of each family found in living
organisms. This was a bold and imagi-
native step forward, which has allowed
us to map complex biological space,
in this case protein space. Its strength
has been that programs have been well
focused, but this has also been its lim-
itation. The functioning proteome is a
network of interactions that changes
over time, between healthy and dis-
eased cells; it is not a reductionist set
of individual protein domains. Interac-
tions include those with other macro-
molecules, with allosteric effectors and
with substrates and small molecule
ligands. These interactions can some-
times be predicted, but not efficiently
or well by current docking software.
Understanding how biological space
limits chemical space remains a chal-
lenge not only for biologists but also
for drug discovery. Although there are
exceptions, it is clear that most current
structural proteomics exercises are
not addressing these challenges. The
question is: should we proceed with
structural proteomics in the same mode
or should we seek further information
for our representative proteins in future
structural proteomics programs?
Inparallel to the structuralproteomics
initiatives, structural biologists have
also recruitedhigh-throughputmethods
to drug discovery and founded compa-
nies like Astex, Sunesis, Syrrx, and
SGX . They have exploited not only
X-ray crystallography but also NMR,
surface plasmon resonance, thermal
shift, isothermal calorimetry, and mass
spectrometry to explore the relation-1342 Structure 15, November 2007 ª2007ship of protein and chemical space,
by screening small molecule com-
pounds (for a review see Congreve
et al., 2005). They have demonstrated
that the libraries of small chemical
compounds of molecular weights less
than 300 provide a very effective way
of exploring chemical space (see Fig-
ure 1) and for providing hits, leads,
and candidate drug molecules. Can
we use this experience together with
that of structural proteomics to define
a new approach? I think we can.
In future structural proteomics pro-
grams we should seek to capture the
conformational states characteristic
of ligand and allosteric binding. How-
ever, we should also explore chemical
space by screening with libraries of
carefully chosen fragments with drug-
like characteristics. With about 100Elsevier Ltd All rights reservedcrystals and not more than 400 frag-
ments in cocktails, X-ray data could
be collected quickly and the analyses
automated for each protein whose
structure is determined.
What would be the value of these
results? They would give clues about
binding sites and possibly functions.
However, they would more directly
provide a basis for drug discovery, es-
pecially useful for the many academic
groups working on difficult targets,
rare diseases, or diseases of poverty.
They would also provide industry with
data for computational approaches
to scan the proteome for off-target
binding of candidate drug molecules,
so optimizing the chance of identifying
side effects. This would be a major
contribution to drug discovery for both
the First World and the Third World,Figure 1. Chemical Fragments Bound to Proteins
Figure courtesy of Astex Therapeutics. Reproduced from Hartshorn et al., 2005.
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ficient and providing a basis for identi-
fying the side effects that decrease the
value of many drugs. The industry is
good at focusing on one target but the
broader proteome is usually beyond
the reach of one company. The greater
knowledge of biological and chemical
space should continue and expandthe impressive impact that structural
proteomics programs like the NIGMS
Protein Structure Initiative are already
having on industry and academia.
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